Global Polycystic Ovarian Syndrome Treatment Market Trends, Analysis, Growth, and Forecast: 2018 to 2027
MarketResearch.biz delivers in-depth insights on the global polycystic ovarian syndrome treatment market in its upcoming report titled, “Global Polycystic Ovarian Syndrome Market Trends, Analysis, Growth, and Forecast: 2018 to 2027”. The global polycystic ovarian syndrome treatment market is estimated to register a CAGR of X.X% in terms of value during forecast period 2018–2027. The report offers in-depth insights, revenue details, and other vital information regarding the global polycystic ovarian syndrome treatment market, and the various trends, drivers, restraints, opportunities, and threats in the target market till 2027. The report offers insightful and detailed information regarding the various key players operating in the global polycystic ovarian syndrome treatment market, their financials, supply chain trends, product launches, key developments, apart from future strategies, acquisitions & mergers, and market footprint. The global polycystic ovarian syndrome treatment market report has been segmented on the basis of drug type, surgery type, and region.
Polycystic ovary syndrome (PCOS) is a common hormonal disorder in women, and is caused by a combination of environmental and genetic factors in which the ovaries accumulate tiny cysts resulting into the enlargement of ovaries with cysts on the outer edges. Some effects of PCOS includes irregular or absent menstrual cycle, excess androgen, excess hair growth, weight gain, and depression. Currently, there is no cure, but the symptoms of PCOS can be minimized with proper treatment and medication.
Weight gain and insulin resistance are two major symptoms associated with PCOS. In addition, increasing prevalence of diabetes and obesity in women are other factors contributing to growth of the global polycystic ovarian syndrome treatment market. Moreover, rising awareness about the disorder globally, coupled with several government and non-profit organizations providing education and support services for women, is anticipated to further drive growth of the global polycystic ovarian syndrome treatment market over the forecast period.
A major factor restraining growth of the global polycystic ovarian syndrome treatment market is easy availability of generic and off label drugs in the market.
However, technological advancements and innovations focusing on development of specific drugs or treatments is expected to create new opportunities for major players in the global polycystic ovarian syndrome treatment market over the forecast period.
North America market dominates the global polycystic ovarian syndrome treatment market in terms of revenue contribution as compared to that of markets in other regions. This is attributed to well-developed healthcare infrastructure and availability of skilled medical personnel, presence of leading manufacturers, and large PCOS patient pool in countries in the region. Europe accounts for second-largest revenue share contribution to the global polycystic ovarian syndrome treatment market, followed by markets in Latin America, Asia Pacific, and Middle East & Africa respectively. The market in Asia Pacific is projected to register comparatively faster growth in terms of revenue over the next 10 years, owing to increasing patients pool and increasing awareness regarding the disorder in some major countries in the region.
Global polycystic ovarian syndrome treatment market segmentation, by drug type:
- Oral Contraceptives
- Ornithine Decarboxylase Inhibitors
- Insulin-Sensitizing Agents
- Aromatase Inhibitors
Global polycystic ovarian syndrome treatment market segmentation, by surgery type:
- Ovarian Wedge Resection
- Laparoscopic Ovarian Drilling
Global polycystic ovarian syndrome treatment market segmentation, by region:
- North America
- Asia Pacific
- Latin America
- Middle East & Africa
Particular Scope Region
- North America
- Rest of Europe
- Asia Pacific
- South Korea
- Rest of Asia Pacific
- Latin America
- Rest of Latin America
- Middle East and Africa
- South Africa
- Rest of Middle East and Africa
Actual Year 2017 Estimated Year 2018 Forecast Period 2018–2028 Revenue in US$
- Sanofi S.A.
- Pfizer Inc.
- Bristol-Myers Squibb Company
- Novartis AG
- Merck & Co., Inc.
- AstraZeneca Plc.
- Abbott Laboratories
- Bayer AG
- Teva Pharmaceutical Industries Ltd.
- Ferring Pharmaceuticals
Request for TOC
Request for Customization
Don't just take our word. We are trusted by these great companies!